DUBLIN, IRELAND--(Marketwired - Apr 28, 2015) - Horizon Pharma plc (
"Throughout my career, I have admired PhRMA's tireless work to support biopharmaceutical research and address patient needs," said Walbert. "It is a privilege to join the Board of Directors and advocate for policies that promote development of important new medicines."
PhRMA represents the country's leading biopharmaceutical research and biotechnology companies, and is devoted to advancing public policies in the Unites States and around the world that support innovative medical research, yield progress for patients today and provide hope for the treatments and cures of tomorrow.
"For years, Tim has served as a leader in the biopharmaceutical field and is dedicated to providing access to important treatments that improve patients' lives," said John Castellani, PhRMA president and chief executive officer. "We are fortunate to welcome Tim to PhRMA's Board of Directors, where his leadership and vision will help us promote a vibrant biopharmaceutical research environment."
Walbert joined Horizon Pharma in 2008 as president and chief executive officer and has served as chairman of the company's board of directors since 2010.
Prior to joining Horizon Pharma, Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Walbert served as executive vice president, commercial operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, Walbert served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. From 1991 to 1998, Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc. and Wyeth.
Walbert also currently serves on the Board of Directors of XOMA Corporation (
About Horizon Pharma plc Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium). Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com .
Contacts: Investors: Robert F. Carey Executive Vice President, Chief Business Officer Email Contact Media: Geoff Curtis Group Vice President, Corporate Communications Email Contact
